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Abstract:  
A series 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines (43 compounds), some of which are 
epidermal growth factor tyrosine kinase inhibitors, were tested for their protozoal toxicity 
using an environmental Tetrahymena strain as model organism. The protozoacidal activity of 
the analogues was found to be highly dependent on a 4-hydroxyl group at the 6-aryl ring, and 
a chiral 1-phenylethanamine substituent in position 4. Further, the potency was affected by 
the aromatic substitution pattern of the phenylethanamine: the unsubstituted, the meta-fluoro 
and the para-bromo substituted derivatives had the lowest minimum protozoacidal 
concentrations (8-16 µg/mL). Surprisingly, both enantiomers were found to have high 
potency suggesting that this compound class could have several modes of action. No 
correlation was found between the compounds protozoacidal activity and the in vitro 
epidermal growth factor receptor tyrosine kinase inhibitory potency. This suggests that the 
observed antimicrobial effects are related to other targets. Testing towards a panel of kinases 
indicated several alternative modes of action. 
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1. Introduction 
 
Diseases caused by parasitic protozoa, as for instance malaria, dysentery, leishmaniasis, and 
human African trypanosomiasis are major causes of mortality throughout the world, thus, the 
study of effects of organic compounds on protozoa is important. Therapeutic agents are 
available,[1;2] however, many of the drugs have critical side effects[3;4] and also resistance is 
emerging.[5;6] Therefore, identification of new lead compounds is required, and inhibition of 
cellular kinase activity has been recognised as a useful strategy.[7-11] Among others, tyrosine 
kinase inhibitors such as Erlotinib, Canertinib and Sunitinib designed for cancer 
chemotherapy have been identified as efficient antiprotozoal agents.[11]  
 
Tetrahymena is a genus of ciliated protozoa. Its members are easily grown and relatively safe 
to handle making them useful model systems for biochemical mechanistic studies in 
eukaryotes.[12] The motility behaviour of Tetrahymena is conveniently used to monitor 
bioactivity and cell toxicity of chemicals.[13-15] Compounds such as diphenols, 
aminophenols, diaminoaromatics, halogenated aromatic nitro compounds, aromatic aldehydes 
and α-haloketones are generally toxic to Tetrahymena. This is due to their ability to undergo 
various reactions with biomacromolecules.[16-19] Tetrahymena do not pose a serious threat 
to human health. However, Legionella in symbiosis with Tetrahymena tropicalis appears 
more resistant and aggressive.[20;21] In addition, infections attributed to members of this 
genus are a problem in closed fish farming. Low molecular weight compounds such as 
Menadione (I),[22] and anti-infective agents such as Niclosamide (II) have been proposed as 
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treatment alternatives.[23] Other compounds with in vitro activity towards Tetrahymena 
include among others Climacostol (III)[24], known antimicrobial agents as Chloroquine[25] 
and Chloroamphenicol[26;27] and antineoplastics such as Necodazole,[28] Figure 1.  
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Figure 1. Structure of compounds I-III with potency towards Tetrahymena and the kinase 
inhibitors Canertinib (IV) and Sunitinib (V). 
 
Tetrahymena are known to have epidermal growth factor (EGF)-like receptors which are 
involved in cell division,[29] and cyst formation.[30] Also other processes such as 
chemotaxis,[31] hormonal imprinting,[32] cell division,[33;34] stress response,[34;35] and 
GTP signalling,[36] are triggered and controlled by kinase activity. Using an environmental 
Tetrahymena isolate as model, we have evaluated the potency of a series of 6-aryl-7H-
pyrrolo[2,3-d]pyrimidine-4-amines as antiprotozoal agents. One goal has been to identify new 
lead compounds for combating protozoa. Secondly, the study could shed light on the toxicity 
profile of this compound class since some of the derivatives are efficient inhibitors of the 
epidermal growth factor receptor tyrosine kinase (EGFR-TK) in vitro.[37]  
 
 
2. Materials and methods 
 
2.1 General 
1H and 13C NMR spectra were recorded with a Bruker Avance 400 spectrometer operating at 
400 MHz and 100 MHz, respectively. 19F NMR was performed on a Bruker Avance 600 
operating at 564 MHz. The 19F NMR shift values are relative to hexafluorobenzene. Coupling 
constants are in Hertz. HPLC (Agilent 110-Series) with a G1379A degasser, G1311A 
Quatpump, G1313A ALS autosampler and a G1315D Agilent detector (230 nm) was used to 
determine the purity of the synthesised compounds. Conditions: a Omrisphere 5 C18 
(100×3.0 mm) column, flow rate 1.0 mL/min, elution starting with H2O+1% TFA/acetonitrile 
(98/2), linear gradient elution for 15 min. ending at acetonitrile/water+1% TFA (90/10), then 
15 min isocratic elution. The software used with the HPLC was Agilent ChemStation. 
Accurate mass determination was performed with EI (70eV) using a Finnigan MAT 95 XL. 
FTIR spectra were recorded on a Thermo Nicolet Avatar 330 infrared spectrophotometer. All 
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melting points are uncorrected and measured by a Büchi melting point instrument. Optical 
rotation was measured with a PerkinElmer Instruments Model 341 Polarimeter. 
 
2.2 Isolation and characterisation of Tetrahymena 
The Tetrahymena strain used was originally isolated from pond water in Norway and was 
identified to the genus level based on its phenotype and on partial sequencing of the 18S 
rDNA-gene. The sequence had 100 % identity with reported sequences for T. iwoffi, T. 
tropicalis and T. furgosoni. The strain was maintained on non-nutrient agar (CCAP, Scotland) 
seeded with a thick suspension of pasteurised E. coli prior to testing. The strain and further 
information on the sequencing studies can be made available on request.  
 
2.3 Determination of minimum protozoacidal (MPC) concentrations  
Stock solutions of the agents were made in DMSO at a concentration of 5120 µg/mL. 
Benzalkonium chloride (stock in water) was included as control. Water was used as dilutant 
producing doubling concentrations of the agents at 128 to 4 µg/mL. These intermediate 
dilutions (50 µL) were pipetted in triplicate into a 96-well, Nunc® round-bottomed microtiter 
plate system (Thermo Fischer Scientific, USA). Addition of 50 µL of the inoculum gave the 
final tested concentration range (2 - 64 µg/mL) and maximally 1.25% DMSO. A positive 
control (no agent), and a negative control (without Tetrahymena) tests were also included. 
Tetrahymena was grown on NNA seeded with a thick pasteurised suspension of E. coli for 48 
h under a humidified atmosphere in the dark at 22 ± 2 °C. After incubation, protozoa were 
harvested and washed as previously described,[38] and resuspended in pasteurised E. coli 
(corresponding to a MacFarland 0.5 standard) at 1 × 104 cells/mL. After incubation for 48 h at 
22 ± 2 °C, wells were examined for motile cells using an inverted microscope. This approach 
enabled the whole content of the well to be visualised. The estimated minimum protozoacidal 
concentration (MPC; 48 h) was the lowest concentration at which no motile cells were seen. 
After examination in the microscope, the whole content of wells was transferred to culture 
dishes containing NNA/pasteurised E. coli. Cultures were examined over a 7-day period with 
an inverted microscope to see if a cell population developed. The MPC value measured 
(MPC; 7 days) was the lowest concentration that prevented the development of even a single 
viable cell in the 7-day period. Each test was performed in triplicate and the results were 
averaged to give the MPC value. 
 
2.4 Kinase profiling 
Compound (R)-25e was profiled utilising a panel of 124 protein kinases in the MRC National 
Centre for Protein Kinase Profiling Service at the University of Dundee (http://www.kinase-
screen.mrc.ac.uk). The compound was tested in vitro, in duplicate, at a final concentration of 
50 nM. For further details of the methodology see Bain et al.[39] 
 
2.5 Synthesis 
Detailed description of the synthesis and characterisation of most of the intermediates and 
tested compounds can be found elsewhere.[37;40] The synthesis and characterisation of the 
new chemical entities are given below. 
 
2.5.1 General procedure thermal amination to 20-24 
The following is representative: 4-chloro-6-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine 
(14) (275 mg, 1.06 mmol) and (S)-1-phenylethanamine ((S)-19i) (0.44 mL, ~3.5 mmol) were 
added to a dry round bottle flask containing 1-butanol (3.5 mL) under argon atmosphere. The 
mixture was heated at 145 oC for 24 h. The precipitate formed upon cooling to rt. was isolated 
by filtration, washed with diethyl ether (25 mL) and dried resulting in a solid. 
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2.5.1.1 (S)-6-(4-Methoxyphenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
((S)-20e) 
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (14) (159 mg, 0.61 mmol)  and (S)-1-
phenylethanamine (19e) (222 mg, 1.84 mmol). This gave 179 mg (0.52 mmol, 85 %) of a 
white solid, mp. 226-228 °C, 
20[ ]Da = +289 (c 0.17, DMSO). Spectroscopic properties were in 
correspondence with that reported previously for the (R)-enantiomer.[40] 1H NMR (400 MHz, 
DMSO-d6) δ: 11.92 (s, 1H, NH, H-7), 8.04 (s, 1H, H-2), 7.73 (m, 3H), 7.43 (m, 2H), 7.30 (m, 
2), 7.19 (m, 1H), 7.02 (d, J=8.8, 2H), 6.96 (bs, 1H, H-5), 5.50 (m, 1H), 3.80 (s, 3H), 1.53 (d, 
J= 7.0, 3H). HRMS (EI): 344.1634 (calcd C21H20N4O, 344.1632, M+). 
 
2.5.1.2 (R)-6-(4-Methoxyphenyl)-N-(1-(4-methoxyphenyl)ethyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine ((R)-20h)  
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
metoxyphenyl)-7H-pyrrolo-[2,3-d]-pyrimidine (14) (238 mg, 0.92 mmol) and (R)-(4-
methoxyphenyl)ethanamine (19h) (288 mg, 1.90 mmol). This gave 220 mg (0.59 mmol, 64%) 
of an off-white solid, mp. 249-251°C, 20[ ]Da = -330.1 (c 0.14, DMSO), purity > 99% (by 
HPLC). 1H NMR (400 MHz, DMSO-d6) δ: 11.89 (s, 1H, NH, H-7), 8.04 (s, 1H), 7.71 (d, 
J=8.9, 2H), 7.64 (d, J=8.4, 1H, NH), 7.34 (d, J=8.7, 2H), 7.02 (d, J=8.9, 2H), 6.94 (s, 1H, H-
5), 6.86 (d, J=8.7, 2H), 5.45 (m, 1H), 3.80 (s, 3H), 3.71 (s, 3H), 1.50 (d, J=7.0, 3H). 13C NMR 
(100 MHz, DMSO-d6) δ: 158.6, 157.9, 154.8, 151.3 (2C), 137.5, 133.4, 127.2 (2C), 125.9 
(2C), 124.5, 114.4 (2C), 113.5 (2C), 103.9, 94.6, 55.2, 55.0, 48.0, 22.9. HRMS (ESI): 
375.1814 (calcd C22H22N4O2, 375.1816, M+H+). IR (neat, cm-1): 3099, 2973, 1588, 1244, 
830. 
 
2.5.1.3 (S)-N-(1-(4-Bromophenyl)ethyl)-6-(4-methoxyphenyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine ( (S)-20i)  
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
methoxyphenyl)-7H-pyrrolo-[2,3-d]-pyrimidine (14) (190 mg, 0.73 mmol) and (S)-1-(4-
bromophenyl)ethanamine (19i) (439 mg, 2.19 mmol). This gave 245 mg (0.58 mmol, 79%) of 
a white solid, mp. 274-275 °C, 
20[ ]Da = +309 (c 0.21, DMSO). Spectroscopic properties were 
in correspondence with that reported previously for the (R)-enantiomer.[37] 1H NMR (400 
MHz, DMSO-d6) δ: 11.93 (s, 1H, NH, H-7), 8.03 (s, 1H, H-2), 7.76 (s, 1H, NH), 7.73 (m, 
2H), 7.49 (m, 2H), 7.38 (m, 2H), 7.02 (m, 2H), 6.94 (d, J=1.8, 1H, H-5), 5.44 (m, 1H), 3.80 
(s, 3H), 1.51 (d, J=7.0, 3H). HRMS (EI): 422.0739 (calcd C21H19BrN4O, 422.0737, M+) 
 
2.5.1.4 6-(4-Methoxyphenyl)-N-(1-naphthalen-1-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-
4-amine (20o) 
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (14) (154 mg, 0.59 mmol) and naphthalen-1-
ylmethanamine (19o) (280 mg, 1.78 mmol). This gave 173 mg (0.45 mmol, 77%) of a white 
solid, mp 278-281°C. 1H NMR (400 MHz, DMSO-d6) δ: 11.98 (s, 1H, NH, H-7), 8.21-8.19 
(m, 1H), 8.14 (s, 1H, H-2), 7.97-7.94 (m, 2H), 7.86-7.84 (m, 1H), 7.71-7.69 (m, 2H), 7.57-
7.52 (m, 3 H), 7.49-7.46 (m, 1H), 7.01-7.00 (m, 2H), 6.89 (s, 1H, H-5), 5.20 (d, J=5.6, 2H), 
3.79 (s, 3H). 13C NMR (100 MHz, DMSO-d6), δ: 159.1, 155.8, 151.8 (2C, overlap), 135.7, 
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134.2, 133.8, 131.5, 128.9, 127.8, 126.6, 126.4 (2C), 126.2, 125.9, 125.7, 124.9, 124.0, 114.9 
(2C), 104.4, 95.0, 55.6, 41.9. IR (neat, cm-1): 3152, 1597,1254,769. HRMS (EI): 380.1632 
(calcd C24H20N4O, 380.1632, M+) 
 
2.5.1.5 (R)-6-(4-Methoxyphenyl)-N-(1-(naphthalen-1-yl)ethyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine ((R)-20p) 
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (14) (144 mg, 0.55 mmol)  and (R)-1-
(naphthalen-1-yl)ethanamine (19p) (285 mg, 1.66 mmol). This gave 162 mg (0.41 mmol, 
74%) of a white solid, mp. 274-276 °C, 
20[ ]Da = -432 (c 0.37, DMSO). Spectroscopic 
properties were in correspondence with that reported previously for the racemate.[37] 1H 
NMR (400 MHz, DMSO-d6) δ: 11.93 (s, 1H, NH, H-7), 8.24 (d, J=8.2, 1H), 8.04 (s, 1H, H-2), 
7.94 (m, 1H), 7.87 (m, 1H), 7.81 (m, 1H), 7.71-7.64 (m, 3H), 7.59-7.45 (m, 3H), 7.01 (m, 
2H), 6.97 (s, 1H, H-5), 6.27 (m, 1H), 3.79 (s, 3H), 1.67 (d, J=6.8, 3H). IR (neat, cm-1): 3131, 
2962 1624, 1251, 828, 775. HRMS (EI): 394.1783 (calcd C25H22N4O, 394.1794, M+). 
 
2.5.1.6 (R)-N-(1-(Naphthalen-1-yl)ethyl)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
((R)-21p) 
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
phenyl)-7H-pyrrolo[2,3-d]pyrimidine (15) (87 mg, 0.38 mmol) and (R)-1-(naphthalen-1-
yl)ethanamine (19p) (195 mg, 1.14 mmol). This gave 107 mg (0.29 mmol, 76%) of a white 
solid. The solid melted at 155-157 °C, but partly re-solidified to a solid melting at 200°C, 
20[ ]Da = -481 (c 1.00, DMSO), purity: 98% (by HPLC). 
1H NMR (400 MHz, DMSO-d6) δ: 
12.07 (s, 1H, NH, H-7), 8.26-8.24 (m, 1H), 8.08 (s, 1H, H-2), 8.01-7.93 (m, 2H), 7.82-7.77 
(m, 3H), 7.67-7.66 (m, 1H), 7.59-7.41 (m, 5H), 7.30-7.27 (m, 1H), 7.14 (s, 1H, H-5), 6.32-
6.25 (m, 1H), 1.68 (d, J=6.8, 3H). 13C NMR (100 MHz, DMSO-d6) δ: 155.3, 152.3, 152.0 
141.3, 133.92, 133.87, 132.3, 131.1, 129.42 (2C), 129.1, 127.7, 127.6, 126.6, 126.0, 125.9, 
124.9 (2C), 123.8, 122.7, 104.4, 60.2, 96.7, 22.3. IR (neat, cm-1): 2976, 1586, 1471, 1311, 
774, 749. HRMS (EI): 364.1683 (calcd C24H20N4, 364.1682, M+). 
 
2.5.1.7 (S)-N-(1-(Naphthalen-1-yl)ethyl)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
((S)-21p) 
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
phenyl)-7H-pyrrolo[2,3-d]pyrimidine (15) (70 mg, 0.30 mmol)  and (S)-1-phenylethanamine 
(19e) (156 mg, 0.91 mmol). This gave 84 mg (23 mmol, 77%) of a white solid, mp. 162-166 
°C, 20[ ]Da = +422 (c 1.00, DMSO), purity: 98% (by HPLC). The spectroscopic properties 
corresponded with that reported for (S)-21p in section 2.5.1.6. HRMS (EI): 364.1682 (calcd 
C24H20N4, 364.1682, M+). 
 
2.5.1.8 (R)-6-(4-Fluorophenyl)-N-(1-(naphthalen-1-yl)ethyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine ((R)-22p) 
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine (16) (64 mg, 0.26 mmol) and (R)-1-(naphthalen-
1-yl)ethanamine (19p) (133 mg, 0.78 mmol). This gave 70 mg (0.18 mmol, 70%) of a white 
solid, mp. 147-150 °C, 
20[ ]Da = -444 (c 0.40, DMSO), purity: 99% (by HPLC). 
1H NMR (400 
MHz, DMSO-d6) δ: 12.07 (s, 1H, NH, H-7), 8.26-8.24 (m, 1H), 8.08 (s, 1H, H-2), 7.99-7.93 
(m, 2H), 7.82-7.80 (m, 3H), 7.67-7.65 (m, 1H), 7.58-7.45 (m, 3H), 7.31-7.27 (m, 2H), 7.09 (s, 
1H, H-5), 6.31-6.25 (m, 1H), 1.68 (d, J=6.8, 3H). 13C NMR (100 MHz, DMSO-d6), δ: 161.9 
(d, J=244.5), 155.3, 152.3 (2C), 152.0, 141.3, 139.9, 133.0, 131.1, 129.1, 128.9 (d, J=2.9), 
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127.6, 126.9 (d, J=7.9), 126.6, 126.0 (d, J=3.5, 2C), 123.8, 122.7, 116.4 (d, J=21.7, 2C), 
104.4, 96.6, 60.2, 22.2. 19F NMR (564 MHz, DMSO-d6, C6F6) δ: -117.1 (m). IR (neat, cm-1): 
2985, 1585, 1496, 1312, 1233, 834, 774. HRMS (EI): 382.1585 (calcd C24H19FN4, 382.1586, 
M+). 
 
2.5.1.9 (S)-6-(4-Fluorophenyl)-N-(1-(naphthalen-1-yl)ethyl)-7H-pyrrolo[2,3-d]pyrimidin-
4-amine ((S)-22p) 
The compound was prepared as described in Section 2.5.1 starting with 4-chloro-6-(4-
fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine (16) (66 mg, 0.27 mmol)  and (S)-1-
phenylethanamine (19p) (137 mg, 0.80 mmol). This gave 76 mg (0.20 mmol, 74%) of a white 
solid, mp. 149-152 °C, 
20[ ]Da = +380 (c 0.13, DMSO), purity: 98% (by HPLC). The 
spectroscopic properties corresponded with that reported for (R)-22p in section 2.5.1.8. 
 
2.5.2 General procedure demethylation of 20 to 25 
The following is representative: (S)-6-(4-methoxyphenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine (20i) was dissolved in dry CH2Cl2 (2 mL) under argon atmosphere. BBr3 
(0.17 ml, ~1.8 mmol) in dry CH2Cl2 (1.5 mL) was added drop wise over 1 h. at 0 °C using a 
syringe pump. Then the mixture was allowed to react at 20 oC for 24 h. The reaction was 
quenched by addition of water (10 mL), and the mixture was extracted with EtOAc (3×25 
mL). The combined organic phase was washed with brine (15 mL), dried over MgSO4 and 
concentrated. The resulting residue was purified by precipitation from acetone (0.5 mL). The 
solid formed was isolated by filtration, washed with diethyl ether (10 mL) and dried. 
 
2.5.2.1 (S)-4-(4-(1-Phenylethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol 
hydrobromide ((S)-25e) 
The compound was synthesised as described in Section 2.5.2 starting from (S)-6-(4-
methoxyphenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (20e) (99 mg, 0.29 
mmol). This gave 56 mg, (0.14 mmol, 47%) of a white solid, mp > 300 °C, 20[ ]Da  = +289 (c 
0.17, DMSO). purity > 98% (by HPLC) Spectroscopic properties were in correspondence 
with that reported previously for the (R)-enantiomer.[37] 1H NMR (400 MHz, DMSO-d6) δ: 
12.98 (s, 1H, NH, H-7), 9.83 (br s, 1H, OH), 9.55 (br s, 1H, NH), 8.30 (s, 1H, H-2), 7.66 (m, 
2H), 7.50-7.48 (m, 2H), 7.39 (m, 2H), 7.32-7.29 (m, 1H), 7.24 (s, 1H, H-5), 6.89 (m, 2H), 
5.37 (m, 1H), 1.66 (d, J=6.5, 3H). HRMS (EI): 330.1475 (calcd C20H18N4O, 330.1475, M+). 
 
2.5.2.2 (S)-4-(4-(1-(4-bromophenyl)ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol 
hydrobromide ((S)-25i) 
The compound was synthesised as described in Section 2.5.2 starting from (S)-N-(1-(4-
bromophenyl)ethyl)-6-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (20i) (134 
mg, 0.32 mol). This gave 83 mg (0.17 mmol, 52%) of a white solid, mp. 274-276 °C, 20[ ]Da  = 
+272 (c 0.28, DMSO), purity > 97% (by HPLC). Spectroscopic properties were in 
correspondence with that reported previously for the (R)-enantiomer.[37] 1H NMR (400 MHz, 
DMSO-d6) δ: 12.94 (s, 1H, NH, H-7), 9.82 (br s, 1H, OH), 9.47 (br s, 1H, NH), 8.29 (s, 1H, 
H-2), 7.65 (m, 2H), 7.58 (m, 2H), 7.44 (m, 2H), 7.16 (s, 1H, H-5), 6.88 (m, 2H), 5.37 (m, 
1H), 1.63 (d, J=6.6, 3H. HRMS (EI): 408.0581 (calcd C20H17Br79N4O, 408.0580, M+).  
 
2.5.2.3 4-(4-(Naphthalen-1-ylmethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol 
hydrobromide (25o) 
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The compound was synthesised as described in Section 2.5.2 starting from 6-(4-
methoxyphenyl)-N-(naphthalen-1-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (20o) (117 
mg, 0.31 mmol) and BBr3 (0.29 mL, 3.1 mmol). This gave 74 mg (0.20 mmol, 66%) of a 
white solid, mp > 300 °C. purity > 98% (by HPLC). 1H NMR (400 MHz, DMSO-d6) δ: 13.01 
(s, 1H, H-7), 9.82 (s, 1H, OH), 8.36 (s, 1H, H-2), 8.15-8.13 (m, 1H), 8.04-8.02 (m, 1H), 7.97-
7.95 (m, 1H), 7.66-7.60 (m, 4H), 7.54-7.7.50 (m, 2H), 7.17 (s, 1H, H-5), 6.87-6.89 (m, 2H), 
5.26 (bs, 2H). 13C NMR (100 MHz, DMSO-d6) δ: 158.5, 149.9, 148.6, 142.8, 138.1, 133.9, 
132.1, 131.3, 129.1, 128.9, 127.2 (2C), 127.1, 126.7, 126.1, 125.4, 124.1, 121.7, 116.4 (2C), 
103.5, 96.8, 43.9. IR (neat, cm-1): 3123, 1643, 1612, 1493, 1178, 757. HRMS (EI): 366.1471 
(calcd C23H18N4O, 366.1475, M+). 
 
2.5.2.4 (R)-4-(4-(1-(naphthalen-1-yl)ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-
yl)phenol ((R)-25p) 
The compound was synthesised as described in Section 2.5.2 starting (R)-6-(4-
methoxyphenyl)-N-(1-(naphthalen-1-yl)ethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine ((R)-20p) 
(113 mg, 0.29 mmol). This gave 58 mg (0.15 mmol, 53%) of a white solid, mp > 300 °C. 
20[ ]Da  = -379 (c 0.26, DMSO) purity > 98% (by HPLC). Spectroscopic properties were in 
correspondence with that reported previously for the racemate.[37] 1H NMR (400 MHz, 
DMSO-d6) δ: 12.98 (s, 1H, NH, H-7), 9.82 (br s, 1H, OH), 9.55 (br s, 1H, NH), 8.30 (s, 1H), 
8.14 (s, 1H, H-2), 8.00 (m, 1H), 7.91 (m, 1H), 7.64-7.57 (m, 5H), 7.54-7.50 (m, 1H), 7.26 (s, 
1H, H-5), 6.89-6.87 (m, 2H), 6.09 (m, 1H), 1.78 (d, J=6.5, 3H). HRMS (EI): 380.1635 (calcd 
C24H20N4O, 380,1637, M+). 
 
2.5.2.5 (S)-4-(4-(1-(Naphthalen-1-yl)ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-
yl)phenol hydrobromide ((S)-25p) 
The compound was synthesised as described in Section 2.5.2 starting (S)-6-(4-
methoxyphenyl)-N-(1-(naphthalen-1-yl)ethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine ((S)-20p) 
(73 mg, 0.19 mmol). This gave 48 mg (0.13 mmol, 68%) of a white solid, mp > 300 °C. 20[ ]Da  
= +389 (c 0.16, DMSO) purity > 99% (by HPLC). Spectroscopic properties were in 
correspondence with that reported previously for the racemate.[37] and that described for (R)-
25p in section 2.5.2.4. 
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3. Result and Discussion 
 
3.1 Synthesis 
The pyrrolopyrimidines were synthesised as described previously, Scheme 1.[37;41;42] 
N
N HN
R2
OH
H
N
R
EtO2C
H2NH2N OEt
ONH
O
R
Br
H2N H
O POCl3
+
HCl
Formic acid
NaOEt/EtOH
DMF, 150oC 90oC
O
R
HO
O
R
O
O
O
R
OH
O
+ +
N
N HN
R
Cl
14-18
N
N HN
R
N
Ar
R1H 20-24
NH2
CH3
NH2
R2
NH2
CH3
R2
NH2
CH3
NH2
q
CH3
R2= 
H (a),
 p -F (b), 
m-F (c),
o-F (d).
R2= 
H (e), F (f), 
Me (g) OMe (h),
Br (i), CF3 (j).
R2=
F (k),
Me (l).
R2=
F (m),
Me (n).
R2
Ar R1
NH2
19a-q
NH2
R1
R1= 
H (o), 
CH3 (p).
N
N HN
OH
N
Ar
R1H 25
BBr3
Amines 19a-q
1-5 6 7 8
1-5
9-13
+
R= OMe
R2
R= 
MeO (1, 9, 14, 20)
H (2, 10, 15, 21)
F (3, 11, 16, 22)
Br (4, 12, 17, 23)
CN (5, 13, 18, 24)
145oC
 
Scheme 1. Synthesis of 20-25 using the amines 19a-q. 
 
The first step forming the pyrroles 1-5 gave mediocre yields. We found that formation of 6-8 
was the main reason for the loss in yield. The alcohol 6 may be caused by water generated in 
the pyrrole cyclisation, whereas the esters 7 and 8 most likely originate from fragmentation of 
the unstable aminoimidate. An increase in yield of 1-5 was seen when using >2 equivalents of 
the aminoimidate and 3 equivalents of sodium ethoxide. It has previously been suggested that 
such pyrroles are UV labile.[42] Discolouration of the products was seen on storage in DMSO 
for one day at room temperature. Cyclisation of 1-5 using formamide gave the 4-
hydroxypyrrolopyrimidines 9-13 which all were crystalline and easily isolated. Standard 
chlorination gave 14-18, which also were conveniently isolated and purified if full conversion 
was obtained in the reaction. In the next step, thermal nucleophilic aromatic substitution on 
14-18 was performed using various amines. Compound 14 was reacted with 19a-q giving 
20a-q, while the 4-chloropyrrolopyrimidines 15-18 were mainly substituted with 19e-f and 
19p, giving the corresponding 4-amino derivatives 21-24. Deprotection of the methoxy 
derivatives 20 with boron tribromide gave the phenolic compounds 25. Twelve of the 
compounds reported in this study are new chemical entities. 
 
3.2 Toxicity towards Tetrahymena 
The Tetrahymena strain used in this study was originally isolated from pond water in Norway. 
It was observed that this isolate grew faster and was more vigorous than several of our culture 
collection Tetrahymena strains. These observations were considered important when choosing 
it as a test strain for the present study. Benzylalkonium chloride was used as a control in the 
testing showing a MPC value of 8 µg/mL. We first investigated the effect of compounds 
having benzylamines, chiral 1-phenylethanamines and 1-naphthylethanamines as substituents 
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in Fragment B (see Table 1), and methoxy, hydrogen, fluoro, bromo and cyano as R in 
Fragment A.  
 
 
Table 1. Activity of the pyrrolopyrimidines 20-24 and 25o-p towards Tetrahymena. 
R=
MeO (20)
H (21)
F (22)
Br (23)
CN (24)
OH (25)
N
N HN
R
N
Ar
R1H
R1=H, CH3, Et
Fragment A
Fragment B
R2
Ar:
6
4
 
Entry Substance R R1 Ar/R2 
MPC µg/mL  
(48 h)a) 
1 20a OMe H H >64 
2 20b OMe H p-F >64 
3 (R)-20e OMe CH3 H >64 
4 (S)-20e OMe CH3 H >64 
5 (R)-20h OMe CH3 p-MeO >64 
6 20o OMe H C10H7 >64 
7 (R)-20p OMe CH3 C10H7 32b) 
8 (S)-20p OMe CH3 C10H7 >64 
9 (R)-20r OMe Et H >64 
10 21c H H m-F >64 
11 21e H CH3 H >64 
12 (R)-21f H CH3 p-F >64 
13 (R)-21p H CH3  C10H7 >64 
14 (S)-21p H CH3 C10H7 >64 
15 22c F H m-F >64 
16 (R)-22e F CH3 H >64 
17 (R)-22f F CH3 p-F >64 
18 (R)-22p F CH3 C10H7 >64 
19 (S)-22p F CH3 C10H7 >64 
20 (R)-23e Br CH3 H >64 
21 (R)-23f Br CH3 p-F >64 
22 (R)-24e CN CH3 H >64 
23 (R)-24f CN CH3 p-F >64 
24 25o OH H C10H7 64 
25 (rac)-25p OH CH3  C10H7 64 
26 (R)-25p OH CH3 C10H7 32a) 
27 (S)-25p OH CH3  C10H7 64 
a) The MPC values were determined by averaging three parallel measurements. b) MPC =32 also after 7 days.  
 
Most of the compounds were synthesised as their (R)-enantiomers, but the (S)-enantiomers of 
the methoxy substituted compound 20e, and 20p, 21p and 22p having a 1-
naphthylethanamine substituent at C-4 were included to investigate the importance of 
stereochemistry. Testing revealed that the (R)-naphthyl derivative 20p had an MPC-value of 
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32 (Table 1, entry 7), while other derivatives with R=OMe, H, F, Br and CN did not possess 
protozoacidal activity with respect to Tetrahymena in the lower µg/mL concentration range.  
 
Solubility challenges were encountered when some of these compounds were tested, the 
investigation was continued with the naphthylic compounds 25o-p which had a hydrophilic 
phenolic group in fragment A, (Table 1, entries 24-27). However, no drastic improvement in 
potency was observed. The (R)-enantiomer of 25p (Table 1, entry 26) was the most potent 
and gave a similar MPC value to that of the methoxy derivative (R)-20p (Table 1, entry 7).  
 
Then we decided to evaluate the effect of the substitution pattern in fragment B by varying R1 
(hydrogen, methyl and ethyl) and including mono ortho, meta or para R2-groups, while 
keeping the phenolic unit in fragment A. The compounds tested and their potencies towards 
Tetrahymena are compiled in Table 2.  
 
Table 2. Activity of compounds 25 towards Tetrahymena. 
N
N HN
OH
N R1H
R1=H, CH3, Et
Fragment B
R2
 
Entry Substance R R2 MPC µg/ml  
(48 h)a) 
MPC µg/ml (7 
d) a) 
1 25a H H >64 >64 
2 25b H p-F >64 >64 
3 25c H m-F >64 >64 
4 25d H o-F >64 >64 
5 (R)-25e CH3 H 8/16 b) 16/16 b) 
6 (R)-25f CH3 p-F 32 32 
7 (R)-25g CH3 p-CH3 >64 >64 
8 (R)-25i CH3 p-Br 8/8b) 8/8 b) 
9 (rac)-25j CH3  p-CF3 32 32 
10 (R)-25k CH3 o-F 64 >64 
11 (Rac)-25l CH3 o-CH3 64 >64 
12 (R)-25m CH3 m-F 16 16 
13 (Rac)-25n CH3 m-CH3 32 32 
14 (R)-25q Et H 32 32 
15 (S)-25e CH3  H 8/16 b) 8/16 b) 
16 (S)-25i CH3  Br 8 16 
a) The MPC values were determined by averaging three parallel measurements. b) Values given represent a 
second triplicate ground of testing. 
 
The unsubstituted benzylamine derivative 25a and three fluoro substituted benzylamine 
derivatives, 25b-d, were all inactive in the concentration range tested (Table 2, entries 1-4). 
However, to our satisfaction (R)-25e, PKI-166,[43] having a para-hydroxyphenyl at C-6 and 
a 1-phenylethanamine substituent as C-4, proved to be potent (MPC: 8-16 µg/mL Entry 5), 
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indicating the importance of a chiral centre. Keeping the chiral R1 group as methyl, and 
introducing rather conservative variations in the para position in terms of size and electronic 
properties, gave an MPC = 32 µg/mL for the fluoro derivative 25f, while the methyl analogue 
25g was inactive. By changing the para substituent to bromo, (R)-25i, a MPC value of 8 
µg/mL was obtained. Compared to the activity of the fluoro containing compound 25f this 
indicates that a combination of both increased size and polarisability might be beneficial for 
achieving good potency. Also, the racemic trifluoromethyl derivative (rac)-25j showed 
activity (MPC = 32 µg/mL). Ortho and meta substitution by fluoro or a methyl substituent 
lowered the toxicity, but the meta-fluoro derivative 25m showed appreciable protozoacidal 
activity (MPC: 16 µg/mL, entry 13). It was further investigated how the potency was affected 
by extending the chain length of R1, but the result for 25q containing a 1-phenylpropanamine 
substituent at C-4 (MPC = 32 µg/mL, entry 14) did not encourage further evaluation. To 
verify the importance of stereochemistry for the toxicity profile of these compounds we also 
synthesised and analysed for the effect of the (S)-enantiomers of the 1-phenylethanamine 
containing 25e and its para-bromo substituted derivative 25i. Both were found to be highly 
potent (Table 2, entries 15-16).  
 
Some of the compounds evaluated in this study are efficient inhibitors of EGFR-TK in 
vitro.[37] These kinases depends on activation from the epidermal growth factor (EGF), 
which is a known signalling polypeptide in Tetrahymena.[44] However, we did not find any 
correlation between the in vitro activity towards EGFR-TK and the MPC values. This might 
indicate that receptors found in Tetrahymena are structurally different to the human version. 
To investigate if other kinases might be the target, the para-hydroxyphenyl derivative 25e 
was evaluated against a panel of 124 kinases. Low inhibitory potency was observed in most 
cases (data not shown). Kinases which were inhibited to a degree of 25% or more at 50 nM 
are compiled in Figure 2. Of these kinases, protein kinase B,[45-47] calmodulin dependant 
enzymes,[48;49] protein kinase C,[9;50] and ERK1 type proteins,[51] are found in protozoa 
and represent possible sites of action for the pyrrolopyrimidines. 
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Figure 2. Effect of 25e (50 nM) on the activity of a selection of kinases. PKCα: Protein kinase 
C alpha; JNK2: c-Jun N-terminal kinase/mitogen-activated protein kinase, TrkA: 
Neurotrophic tyrosine kinase receptor type 1, ERK1: extracellular-signal-regulated kinase; 
IKKe: inhibitory κB kinase, MAPKAP-K3, MAPK-activated protein kinase 3; CAMK 1: 
calmodulin-dependent kinase: MINK1: misshapen-like kinase 1 VEGFR: vascular endothelial 
growth factor receptor, Yes 1: Yamaguchi sarcoma viral oncogene homologue. PKBb: protein 
kinase B. 
 
The toxicity/potency of the compounds presented in this study against Tetrahymena crucially 
depended on the presence of a para phenolic group in fragment A. This might be due to better 
solubility and bioavailability than for 20-24, or that the hydroxyl function engages in critical 
bonding interaction. In T. pyriformis there is evidence for a transmembrane efflux pump as a 
detoxification mechanism, preferably excluding lipophilic compounds.[52] This might be an 
alternative explanation for the observed toxicity differences seen on introduction of the 4-
hydroxyl group in fragment A. As Tetrahymena has only limited CYP-450 dependent 
metabolism activity,[53] it is less likely that the toxicity is due to oxidation of the para-
hydroxyphenyl unit of 25 leading to aromatic 1,2-dienones, which are typical Michael 
acceptors in reaction with bio macromolecules.[16;18] The low level of CYP-450 enzymes 
should also exclude the possible formation of active compounds from putative precursors 
such as the C-6 phenyl substituted derivative 21. Furthermore, the MPC values were affected 
by the substitution pattern and the presence of a chiral centre in fragment B. All the above 
indicates that there is a specific mode of action involving a defined 3-dimentional receptor 
target. However, the fact that both enantiomers showed toxicity is suggesting that the 
pyrrolopyrimidines could have multiple modes of action, or that the target is rather flexible.  
 
As a model for unspecific toxicity the study shows that introduction of a 4-hydroxyl group in 
fragment A could be problematic for EGFR-TK inhibitors, but also that the toxicity profile 
could be modulated by the substitution pattern both in fragment A and B. Human toxicity 
issues have in fact been seen for 25e.[54]  
 
4. Conclusion 
A series of pyrrolopyrimidines have been tested for their protozoacidal activity against 
Tetrahymena. Five compounds were found to be highly active (MPC 8-16 µg/mL). The 
identified compounds do not contain the typical groups which trigger non specific toxicity 
effects. The presence of a para phenolic group in position 6 (fragment A), and a chiral centre 
in the 4-benzylamine (fragment B) enhanced the potency considerably. Ortho-substitution in 
fragment B, and an electron donating methyl group in the para position reduced the toxicity. 
There is no evidence that EGFR-TK kinases are targets for these compounds in Tetrahymena, 
however, kinase profiling identified other potential sites of action. The detailed mechanism 
will be investigated in continuing work. The presented structure-activity relationships could 
be used as guidelines for targeting other, medically more important protozoa.  
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